SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer

  • 0Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.

|

|

Summary

This summary is machine-generated.

P-selectin (SELP) expressed in cervical cancer endothelial cells enhances anti-cancer immunity and improves radiotherapy outcomes. Targeting SELP+ endothelial cells and CD8+ T cell interactions may overcome treatment resistance.

Area Of Science

  • Oncology
  • Immunology
  • Cell Biology

Background

  • P-selectin (SELP) in tumor cells is linked to cancer progression and treatment resistance.
  • SELP expression in cervical cancer (CC) endothelial cells may influence anti-cancer immunity and radiotherapy response.
  • Mechanisms of SELP's role in CC immunity and radiotherapy remain unclear.

Purpose Of The Study

  • Investigate the role of SELP in tumor endothelial cells (TECs) in CC radiotherapy response.
  • Elucidate the mechanisms by which SELP influences anti-cancer immunity.
  • Determine the association between SELP expression and patient survival outcomes.

Main Methods

  • Analysis of tumor tissue samples from 205 CC patients undergoing radiotherapy.
  • Single-cell RNA sequencing (scRNA-seq) of 42,159 cells from eight CC patients.
  • Bulk RNA sequencing of 187 radiotherapy-treated CC patients.

Main Results

  • Elevated SELP expression in TECs correlated with improved radiotherapy survival outcomes.
  • SELPhigh group showed enriched immune pathways and reduced proliferation/angiogenesis.
  • Increased CD8+ T cell infiltration and ACKR1 expression were observed in SELPhigh tumors.
  • SELP+ TECs and CD8+ T cells interact via the ACKR1-CCL5 axis, enhancing radiotherapy efficacy.

Conclusions

  • SELP+ TECs play a crucial role in enhancing CC radiotherapy response through interaction with CD8+ T cells.
  • The ACKR1-CCL5 pathway mediates the crosstalk between SELP+ TECs and CD8+ T cells.
  • Targeting this SELP+ TEC:CD8+ T cell crosstalk offers potential therapeutic strategies against treatment resistance in CC.